Circio Holding ASA: Registration of share capital increase following conversion of convertible bonds

20 Jun 2025 11:01 CEST

Oslo, 20 June 2025: Reference is made to the stock exchange announcement by
Circio Holding ASA (OSE:CRNA) (the "Company") on 17 June 2025, regarding the
requested conversion of convertible bonds by Atlas Special Opportunities, LLC.

The share capital increase has now been registered with the Norwegian Register
of Business Enterprises (Nw. Foretaksregisteret). The Company's new share
capital is NOK 61,345,650.00 divided into 102,242,750 shares, each with a
nominal value of NOK 0.60.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com ()

Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com ()

About Circio

Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing powerful circular RNA
vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression
platform for novel DNA, RNA and viral therapeutics. The proprietary circVec
technology is based on a modular genetic cassette design for efficient
biogenesis of multifunctional circRNA inside cells, which can be deployed in
multiple therapeutic settings, including genetic medicine, cell therapy and
chronic disease. The circVec platform has demonstrated up to 15-fold enhanced
and more significantly more durable protein expression vs. classic mRNA vector
systems and has the potential to become a new gold-standard platform
technology for nucleic acid and viral therapeutics in the future. The circRNA
R&D activities are being conducted by the wholly owned subsidiary Circio AB
based at the Karolinska Institute in Stockholm, Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology
program, TG01, through external collaborations. TG01 targets RAS-mutated
cancers and is being tested in two clinical trials in Norway and the USA run
through academic networks and industry partnerships. TG01 is a therapeutic
peptide vaccine adjuvanted by STIMULON QS-21 licensed from Antigenics Inc, a
wholly owned subsidiary of Agenus Inc. STIMULON is a trademark of SaponiQx
Inc., a subsidiary of Agenus

More information:
Access the news on Oslo Bors NewsWeb site